Gilead, having resolved manufacturing issues, forges ahead with HIV drug
Bio Pharma Dive
MAY 17, 2022
The company can now resume testing in nearly a dozen studies that were paused due to FDA concerns about interactions between the drug, lenacapavir, and the glass vials in which it was contained.
Let's personalize your content